Pfizer scraps daily weight loss pill after liver injury in one patient [CNBC]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: CNBC
The patient's liver enzymes “recovered rapidly” after they stopped taking the pill, which is an oral GLP-1 drug called danuglipron. The patient had elevated liver enzymes, which often indicate damage to cells in the liver, but did not experience any liver-related symptoms or side effects, a Pfizer spokesperson told CNBC. The announcement adds to a string of setbacks in the company's bid to win a slice of the booming market for GLP-1s, which mimic gut hormones to tamp down appetite and regulate blood sugar. on Monday said it would end development of its experimental after a patient experienced a liver injury that was potentially caused by the drug in a trial. The patient did not experience any liver-related symptoms or side effects, a Pfizer spokesperson said in a statement. They added that the patient's liver enzymes “recovered rapidly” after they stopped taking the pill, which is an oral GLP-1 drug called danuglipron. The statement suggests that the patient's liver enzymes w
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Form Health Simplifies GLP-1 Coverage Opportunities for Employers with Transparent, Predictable Pricing [Yahoo! Finance]Yahoo! Finance
- These people lost their sense of taste. Are GLP-1s to blame? [USA TODAY]USA TODAY
- Healthcare Stocks: Outlook For 2026 [Seeking Alpha]Seeking Alpha
- Lawsuits alleging GLP-1 drugs led to blindness to be centralized [Seeking Alpha]Seeking Alpha
- Update: Market Chatter: Eli Lilly Could Get FDA Decision for Weight-Loss Pill Orforglipron by March 2026 [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website